The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
Canagliflozin disrupts T cell activation
Nature Reviews Nephrology, Published online: 27 June 2023; doi:10.1038/s41581-023-00739-4Canagliflozin disrupts T cell activation (Source: Nature Reviews Nephrology)
Source: Nature Reviews Nephrology - June 27, 2023 Category: Urology & Nephrology Authors: Monica Wang Source Type: research
The Prevalence of Severely Increased Albuminuria in the Type 2 Diabetes Population with Chronic Kidney Disease of Low Socioeconomic Status in San Juan: A Population in Need of Improved Accessibility to Disease-Modifying Therapy
CONCLUSION: There is a scarcity of studies regarding the prevalence of severely increased albuminuria in type 2 diabetics with CKD and this study contributes to the literature. On analysis of associations, statistical significance not reached likely due to small sample size.PMID:37352533 (Source: Puerto Rico Health Sciences Journal)
Source: Puerto Rico Health Sciences Journal - June 23, 2023 Category: International Medicine & Public Health Authors: Gabriel I Irizarry-Villafa ñe Alex Gonz ález-Bóssolo Source Type: research
